שולי רווח נקי Coeptis Therapeutics Inc. (COEP)

לוגו גרפי של Coeptis Therapeutics, Inc. (COEP)

Coeptis Therapeutics (COEP) fully delegates production and clinical trials to third-party organizations, relying heavily on external partners. Strict internal oversight of regulations ensures the seamlessness of these processes. The company's commercial profit margin demonstrates current business stability, with the parameter value equal to -800.40. Simultaneously, the corporation is implementing emission filtration systems and transitioning to renewable energy in its laboratories.

COEP: רווחיות נקייה של החברה coeptistx.com 28.04.2023 - 09.05.2026

פילוחי נתונים אנליטיים מרוכזים עבור Coeptis Therapeutics Inc. (COEP)

- שער מניה ותחזית מחירי מומחים:
אנליטיקה מסכמת של החברה:Coeptis Therapeutics Inc., COEP
מוצר המיוצר על ידי Coeptis Therapeutics, Inc.

Coeptis Therapeutics (COEP) is currently in the early preclinical research stage and lacks stable revenue streams. This indicator is calculated as the ratio of net income to total gross income for the period, measuring the efficiency of converting revenue into final capital. For this company, the metric reflects a critical dependence on external financing. An analysis of the company's sales margins allows for an assessment of the business's financial stability amid high uncertainty.